May 11 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO
* Q1 loss per share $0.13
* To complete aura ln clinical trial, undertake further
development of voclosporin, co will need to raise additional
funds within next 12 months
* Q1 earnings per share view $-0.14 -- Thomson Reuters
I/B/E/S
* Aurinia reports first quarter 2016 financial results and
operational highlights
Source text for Eikon: ID:nBwc8xPV2a
Further company coverage: AUP.TO
(Bengaluru Newsroom +1-646-223-8780)